Thank you, Madam Chair.
Thank you to our witnesses.
I have four questions; I hope I will have enough time to put all of them to you. I will be very brief, in order for you to have the opportunity to answer them.
At the present time, we have 1.8 million doses of non-adjuvanted vaccine intended for pregnant women. Dr. Grondin was telling us last week that there was too much vaccine for this population group and therefore that other people would be able to receive the non-adjuvanted vaccine doses not needed for pregnant women.
Given the shortage that was announced approximately two weeks or more ago, the supplier having had to shift its production from the adjuvanted to the non-adjuvanted vaccine, and given also that we had ordered 200,000 doses of non-adjuvanted vaccine from Australia — which is probably sufficient to vaccinate pregnant women, of whom there are about 200,000 —, I am simply wondering why, when you saw that you had enough vaccine for pregnant women, you did not ask the supplier to concentrate production on the adjuvanted vaccine, with the option of producing non-adjuvanted doses later on if supply was lacking.